Please assess the completion status of the following clinical trial:

Trial Title: Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine -

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 20 and over (at the time of consent given)~* Gender and inpatient or outpatient: Irrelevant~* Patients diagnosed with Grade A or Grade B mild reflux oesophagitis (according to the Los Angels classification) through endoscopic test~* Patients who complained about heartburn symptom within one week prior to the enrollment~Exclusion Criteria:~* Patients whose heartburn symptom has been disappeared (not been observed at all) during the observation period (Check before official enrollment)~* Patients in ill compliance with dosing the investigational product for the observation period (Not more than 75%, check from the patient dairy before official enrollment)~* Patients the investigator/sub-investigator assessed difficult to complete the patient diary during the treatment period because the patient diary for the observation period has too many deficiencies. (Check before official enrollment)~* Patients with complication of gastric/duodenal ulcer (scarring acceptable)~* Patients with complication of Barrett lining over the site exceeding 3 cm of esophageal distal portion~* Patients who have received the normal dose of H2 receptor antagonist or proton pump inhibitor (PPI) for 8 weeks in vain~* Patients whose Helicobacter pylori was successfully eradicated within 24 weeks~* Patients with medical history of upper gastrointestinal tract excision~* Patients with complication of angina pectoris~* Patients who have received treatment of any other investigational product within 12 weeks~* Patients who showed any of the following values at the laboratory tests before official enrollment: Hemoglobin: \< 9.5 g/dL, WBC: \< 3,000/mm\^3, Thrombocytes: \< 75,000/mm\^3, AST and ALT : ≥ 100 IU/L, Creatinine: ≥ 1.5 mg/dL These should be assessed using the current test values from the blood drawn within 4 weeks prior to official enrollment.~* Patients with complication of serious cardiac disorder (Grade 3 or above under PAB/SD Notification No. 80) For example, patients with triplet or more ventricular premature contractions (multi-sources) or using a pacemaker~* Patients with medical history of serious hypersensitivity to drugs (Grade 3 or above under PAB/SD Notification No. 80)~* Patients who receive treatment of cancer~* Women of confirmed or potential pregnancy, those who wish to become pregnant, and breast feeding women~* Patients having any other condition that, in the opinion of the investigator/sub-investigator disqualifies them for the trial

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Lafutidine group
- 2 (Type: ACTIVE_COMPARATOR): Famotidine group
- 3 (Type: PLACEBO_COMPARATOR): Placebo group

Based on this trial design, predict the completion outcome and termination type (if applicable).